Navigation Links
Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
Date:7/17/2011

PHILADELPHIA The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now know that these women should get trastuzumab and potentially chemotherapy, even if cancer spreads to the brain."

"Women with HER2-positive breast cancer have a reasonable chance of living a long time with their disease, and they should be given aggressive therapy where appropriate," added Brufsky, professor of medicine and associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Ten to 16 percent of women with advanced breast cancer develop central nervous system metastases, the researchers wrote in their study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Brufsky and colleagues used data from the registHER study to evaluate the incidence, potential risk factors and outcomes for patients with HER2-positive breast cancer. They evaluated how patients with HER2-positive breast cancer develop brain metastases, and followed them to examine what happens thereafter.

Of the 1,023 women newly diagnosed with HER2-positive metastatic breast cancer, 377 had central nervous system metastases.

Patients with central nervous system metastases were younger, and more likely to have hormone receptornegative disease and higher disease burden compared with those whose cancer did not spread to the brain. In addition, for those patients without central nervous system metastases at initial diagnosis, cancer progressed to the brain about 13 months after diagnosis.

For those diagnosed with central nervous system metastases, treatment with trastuzumab, chemotherapy or surgery was each associated with a significant improvement in overall survival: trastuzumab 17.5 months vs. no trastuzumab 3.8 months; chemotherapy 16.4 months vs. no chemotherapy 3.7 months; and surgery 20.3 months vs. no surgery 11.3 months.

"It is surprising that chemotherapy/trastuzumab adds to these women's survival," Brufsky said. "We thought that the brain metastases would be dominant in this regard no matter what therapy."


'/>"/>

Contact: Tara Yates
Tara.Yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
2. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
3. York U researchers uncovering how ovarian cancer resists chemotherapy
4. Why chemotherapy causes more infertility in women than in men
5. A loose grip provides better chemotherapy
6. Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy
7. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
8. Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer
9. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
10. Identifying subsets of patients who will respond to subsequent lines of chemotherapy
11. New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology: